Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer

• Main Authors: Faten Shehadeh-Tout (Author), Heloisa H. Milioli (Author), Suraya Roslan (Author), Patric J. Jansson (Author), Mahendiran Dharmasivam (Author), Dinny Graham (Author), Robin Anderson (Author), Tharushi Wijesinghe (Author), Mahan Gholam Azad (Author), Des R. Richardson (Author), Zaklina Kovacevic (Author)
• Format: Book
• Published: Elsevier, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The estrogen receptor-α (ER-α) is a key driver of breast cancer (BC) and the ER-antagonist, tamoxifen, is a central pillar of BC treatment. However, cross-talk between ER-α, other hormone and growth factor receptors enables development of de novo resistance to tamoxifen. Herein, we mechanistically d...